Jiao J,Li WW,Shang YH,Li XF,Jiao M. .2023 .Clinical effects of Chemotherapy combined with Immunotherapy in patients with advanced NSCLC and the effect on their nutritional status and immune function. Pak J Med Sci, 10(2) : 6365-408.
Chen P,Liu Y,Wen Y,Zhou C .2022 .Non-small cell lung cancer in China. Cancer Commun (Lond), 10(10) : 937-970.
Siegel RL,Miller KD,Fuchs HE,Jemal A .2021 .. , 10(1) : 7-33.
Wu SG,Shih JY .2018 .Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer, 10(1) : 38.
Costa C,Molina MA,Drozdowskyj A,Giménez-Capitán A,Bertran-Alamillo J,Karachaliou N .2014 .The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res, 10(7) : CCR13-2233.
Bethune G,Bethune D,Ridgway N .2010 .Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis, 2(1) : 48-51.
Cho BC,Han JY,Kim SW,Lee KH,Cho EK,Lee YG,Oncol J Thorac .2021 .A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. , 11(4) : 558-567.
Elebiyo TC,Rotimi D,Evbuomwan IO,Maimako RF,Iyobhebhe M,Ojo OA .2022 .Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy. Cancer Treat Res Commun, 10 : 100620.
Su JL,Yen CJ,Chen PS,Chuang SE,Hong CC,Kuo IH .2007 .The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer, 10(4) : 541-545.
Zhang C,Wu T,Shen N. .2022 .Effect of platelet-rich plasma combined with tranexamic acid in the treatment of melasma and its effect on the serum levels of vascular endothelial growth factor, endothelin-1 and melatonin. Pak J Med Sci, 10(8) : 6786-2168.
Cui YJ,Liu J,Liu MM,Zhang HZ .2021 .Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer. Pak J Med Sci, 10(4) : 4066-1041.
Yue-Yun C,Ye H,Yang F,Qing L,Pan-Pan L,Zhen-Yu D. Sequential L,Pac J Cancer Prev L .2019 .Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours. , 20(8) : 2415-2420.
Liu M,Li X,Zhang H,Ren F,Liu J,Li Y .2023 .Apatinib added when NSCLC patients get slow progression with EGFR-TKI: A prospective, single-arm study. Cancer Med, 10(24) : 21735-21741.
.2010 .Common Terminology Criteria for Adverse Events (CTCAE) v4. , : 0.
Li F,Zhu T,Cao B,Wang J,Liang L .2017 .Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFRTKI resistance. Eur J Cancer, 07 : 184-192.
Yu Y,Wang Y,Wu L,Xu X,Zhou H,Wang Q .2021 .Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFRTKIs) combined with bevacizumab for advanced non squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study. Medicine (Baltimore), 10(5) : .
Melincovici CS,Boşca AB,Şuşman S,Mărginean M,Mihu C,Istrate M .2018 .Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol, 59(2) : 455-467.
Osude C,Lin L,Patel M,Eckburg A,Berei J,Kuckovic A .2022 .Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer. Cells, 10(10) : 1694.
Zhu N,Dong C,Weng S,Yuan Y,Yuan Y. .2019 .A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and its Response to EGFR-TKIs. J Coll Physicians Surg Pak, 12(12) : S126-S128.
Su J,Zhao Q,Zheng Z,Wang H,Bian C,Meng L .2022 .Prospective Application of Ferroptosis in Hypoxic Cells for Tumor Radiotherapy. Antioxidants (Basel), 10(5) : 921.
Lin WP,Xing KL,Fu JC,Ling YH,Li SH,Yu WS .2021 .Development and Validation of a Model Including Distinct Vascular Patterns to Estimate Survival in Hepatocellular Carcinoma. , 10(9) : .
Zhao H,Yao W,Min X,Gu K,Yu G,Zhang Z,Mutant NSCLC .2021 .The Phase III ACTIVE Study (CTONG1706). J Thorac Oncol, 05(9) : 1533-1546.